.

()
.
,
.
(
1) ( 2).1
10-40%
40-60% .2
20%
1%
.3
:
(), ()
(bemiparin, dalteparin, enoxaparin, nadroparin, tinzaparin),
(acenocumarol, warfarin), a
(Fondaparinux, Rivaroxaban)
(Dabigatran).
(Graduated Compression Stockings -
GCS), (Intermittent
Pneumatic Compression - IPC) .3

( ) Fondaparinux

, ,
anti-
Xa/anti-IIa .

.
.
,

.3

1
 (fondaparinux) -

a. 17
,

. .
, ,
fondaparinux .3

1.

, ,




(, ,
)

The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based

Guidelines. Chest 2004; 126 (3 Suppl): 340S

2.

40-60 40 -60
<40
( , (>40 ,
, , )
)

<40 >60
,
,
,
.

The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based

Guidelines. Chest 2004; 126 (3 Suppl): 341S

2

, 9
American College of Chest Physicians,4
(<0.5%) ( 1)
( 2C) ,
( IPC) ( 1.5%) ( 2C).
( 3%)
( 2), (
2) IPC ( 2C).
( 6%)
( 1) ( 1).

IPC ( 2C).


4 ( 1).

,
IPC,
( 2C).

( 2C) Doppler
( 1).

() 2009,3
: Enoxaparin 40 mg
(4000 anti-Xa IU)/, Dalteparin 5000 anti-Xa IU/mg / , Tinzaparin 4500 anti-Xa
IU/mg , Nadroparin 2850 anti-Xa IU (0.3 ml) / , Bemiparin 3500 anti-Xa
IU/, Fondaparinux 2,5 mg / .
: Enoxaparin 20 mg (2000 anti-Xa IU)/, Dalteparin 2500 anti-Xa IU/mg ,
Tinzaparin 3500 anti-Xa IU/mg , Nadroparin 2850 anti-Xa IU (0.3 ml) / ,
Bemiparin 2500 anti-Xa IU/.

,
,
. ,
3%.
.1
American College of Chest Physicians
(9 )5 :
:
10-14 , fondaparinux, apixaban, dabigatran, rivaroxaban, MKH,
, ( 1)

3
 (IPC) ( 1C).
IPC
.
: 10-14
, fondaparinux, MKH, , ( 1)
(IPC) ( 1C).
IPC
.
(
) 12
12 ( 1).

35 10-14 ( 2).

IPC ( 2C).

IPC apixaban
dabigatran, ( rivaroxaban )
( 1).


( 2C).

Doppler ( 1).

( 2C)
( 2C).5

() 2009,3

: Enoxaparin 40 mg (4000 anti-Xa IU)/ 30
mg (000 anti-Xa IU)/2 ( 12 12-24
), Dalteparin 5000 anti-Xa IU/mg / ( 12
24 ), Tinzaparin 4500 anti-Xa IU/mg
( 12 ), Nadroparin 57 anti-Xa IU/Kg (38 anti-Xa
IU/Kg 12 12
2 3 . 4
57 anti-Xa IU/Kg ), Bemiparin 3500 anti-Xa IU/,
Fondaparinux 2,5 mg / (6-8 ).

4
 (, ) /
3
/ ,
,
.

.
,
,
, ,

.

:

1. .
2. ( < 50.000/ l).
3.

.
4.
.
5. .
6.
( fondaparinux)
.
7. ..
fondaparinux

,
(.. ibuprophen).
8. .

5
 3.

12 6 12 6
#

24 6 12 6

Fondaparinux 36 6 36 12

* 4 1 4 1

3-5
INR < 1.5 .

# , *

.
. , 2009.

,
, (Heparin-induced
thrombocytopenia, HIT type II) 0,5-2%.
, ,
.
.
4
(platelet factor 4, PF4).
,

.
,
,
(direct thrombin inhibitors, DTIs).
,

6

.6
(KH HMB)

.
5 KH HMB.
14 ,

,
. 15
.
> 40% (
)
.
, ,
/
( )
.
,
.
( )
.
.
.
.3

1. Agnelli G. Prevention of Venous Thromboembolism in Surgical Patients.

Circulation. 2004; 110: IV-4-IV-12.
2. Geerts WH, Pineo GF, Heit JA et al. The Seventh ACCP Conference on
Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. Chest
2004; 126 (3 Suppl): 339S.
3. , , . .
.
, 2009.
4. Gould MK, Garcia DA, Wren SM et al. Prevention VTE in nonorthopedic
surgical patients. Antithrombotic therapy and prevention of thrombosis, 9 th
ed: American College of Chest Physicians evidence-based clinical practice
guidelines. Chest 2012; 141(2 Suppl): e227S-e277S.
5. Falck-Ytter Y, Francis CW, Johanson NA et al. Prevention VTE in orthopedic
surgery patients: antithrombotic therapy and prevention of thrombosis, 9 th
ed: American College of Chest Physicians evidence-based clinical practice
guidelines. Chest 2012; 141(2 Suppl): e278S-e325S.
6. , , .
. 2005, 18(2):184-189